CLAIMANTS' ADVISORY COMMITTEE E-NEWSLETTER
Volume 5, No. 14, November 25, 2008
Sybil Niden Goldrich
Ernest Hornsby, Esq.
Dianna
Pendleton-Dominguez, Esq.
This is the 54th e-newsletter
(Vol. 5, No. 14) from the Claimants' Advisory Committee (CAC) in the Dow
Corning bankruptcy Settlement Plan. You were sent a copy of the newsletter
because our records show that you requested to be on the mailing list. If you wish to unsubscribe, click here or to reply to this newsletter, send an email to: info@tortcomm.org. Please do not hit
"Reply" to this email address. Please use the email address: info@tortcomm.org.
Requests for copies of
claim forms or inquiries about the status of a claim should be directed to the
Settlement Facility at info@sfdct.com or
866-874-6099. The Claimants' Advisory Committee does not have access to
individual claimant files to answer these kinds of questions.
1. URGENT
DEADLINE REMINDER TO SETTLING LATE CLAIMANTS: JANUARY 21, 2009 IS THE
DEADLINE TO SUBMIT ALL CLAIM FORMS
NOTE: This reminder applies only
to "Settling Late Claimants." It does not apply to any other claimants in
the Dow Corning case.
If you are a Settling Late
Claimant covered by the Court's Order of December 12, 2007 (Agreed Order
Allowing Late Claimants Limited Rights to Participate in the Plan's Settlement
Facility), then you must submit all claim forms and documents supporting your
claims for Explant, Rupture and Disease or Expedited Release by January 21,
2009. If you have questions about your claim, contact the Settlement Facility
at their toll-free number: 866-874-6099 or contact them by email at: info@sfdct.com. If you need legal assistance with your claim, you can contact
the Claimants' Advisory Committee at info@tortcomm.org.
2. SECOND
RUPTURE PAYMENT AUTHORIZED FOR NOI CLAIMANTS
NOTE: This section applies only
to NOI Claimants. If does not apply to any other claimants in the Dow Corning
case.
The Claims Adminstrator has
authorized NOI Claimants who have an approved Rupture claim to receive their
second installment payment of $10,000 (Class 5). Payments will be mailed
beginning at the end of November 2008.
3. PAYMENTS
CONTINUE TO BE MAILED TO CLAIMANTS WHO WERE SUBJECT TO THE MDL LIENS
As we reported earlier, the
Claims Administrator began issuing payments to claimants whose claims were
previously on hold because of a lien asserted by the MDL-926 Claims Office.
The Court ruled on August 8, 2008 that the MDL-926 Claims Office did not have
standing to assert the liens against claimants in the Settlement Facility. The
first batch of payments was issued in October 2008 and the Settlement Facility
continues to issue payments. If you believe your claim was covered by the
Order of August 8, 2008 and you have not received your payment by the end of
2008, please contact the Claimants' Advisory Committee at info@tortcomm.org.
We are aware that some claims
remain on hold based on a Quality Control audit. We are working through these
claims. If you have been notified that your claim is on hold because of
Quality Control issues and you had a claim in the MDL-926 Claims Office, please
contact us.
4. ATTORNEY
ASSISTANCE AVAILABLE
If you are unrepresented and are
considering filing a disease claim and think you may want legal representation,
please contact the Claimants' Advisory Committee at info@tortcomm.org. We will share with you the names of attorneys and law
firms who have indicated that they are willing to represent claimants with disease
claims. This may be especially urgent for women who have a final disease cure
deadline that will expire or for any claimant considering filing a Disease
claim. You can also contact us by phone at 419-394-0717.
5. INDEPENDENT
ASSESSOR EXECUTIVE REPORT POSTED ONLINE
The Independent Assessor
appointed by the Court has issued its required quarterly report on the projections
of likely amounts of funds to satisfy claim payments. A copy is posted on the
CAC website www.tortcomm.org. The summary report states:
The
Independent Assessor of the Settlement Facility – Dow Corning Trust (SF-DCT)
reviewed the liabilities and assets of the facility as of the end of the second
quarter of 2008 and estimated that the facility would remain solvent under each
of a range of liablity and asset assumptions tested. Until patterns of filing
and claims acceptance become more certain, use of the current estimates for the
purpose of determining whether premium payments can be made is premature.
6. POST
PAYMENT AUDIT LETTERS MAILED BY THE SF-DCT
We were recently informed by
the Settlement Facility that it had mailed "post payment audit letters" to law
firms who represent claimants whose recent mailing address was outdated. The
Settlement Facility asks that law firms provide a copy of the Settlement Sheet
sent to claimants and a copy of the front and back of the cancelled checks sent
to claimants for payment of their SF-DCT award. The CAC has expressed our
concern that the audit seeks documents protected by the attorney-client privilege
(the Settlement Sheet), and that we do not believe law firms are required to provide
this information. However, we do urge all law firms to provide the SF-DCT with
a current address for their clients. We believe this should satisfy the
SF-DCT. If you have any questions about the post payment audit letters or any
other audit letters, please contact us at info@tortcomm.org.
7. PROOF OF
MANUFACTURER ISSUES
If
you have an implant that you are trying to identify based on the following
criteria and your POM was denied by the Settlement Facility, please contact us
at info@tortcomm.org:
size 200
cc, style round and no fixation patch, and implanted between January 1975 and
December 1977
Dow Corning has agreed to re-review these
implant descriptions in the "Individual Review Process" (or IRP) and "approve POM in some situations where the
above indications are present." The Settlement Facility is attempting to
locate medical records that have this type of description for POM as well.
8. CLAIMS PROCESSING
UDPATES
The Claims Administrator
recently reported that processing for claims in Disease Option 1 (Classes 5 and
6) is essentially current. If you have a Disease Option 1 claim that is ready
to submit, now would be a good time to submit it because the wait time is
minimal. The Settlement Facility is currently reviewing Requests for
Additional Information (RAI's) (documents submitted to cure a deficiency) that
were submitted in June 2008.
The Settlement Facility is
processing GCTS claims submitted in March 2006, and Requests for
Additional Information for GCTS claims submitted in February 2008.
The Settlement Facility is
processing SLE claims submitted in June 2007, and Requests for
Additional Information for SLE claims submitted in March 2008.
The Settlement Facility is
essentially current in reviewing claims for Polymyositis, Dermatomyositis and
Scleroderma.
9.
OTHER CLAIM ISSUES
There are
approximately $3.9 million in stale checks issued to 950 claimants. These checks
were not cashed because in many cases claimants had moved and did not provide a
current address to the Settlement Facility. It is extremely important to keep
your address and contact information current with the Settlement Facility and
your attorney if you are represented.
If you move, let the Settlement Facility know by sending them a letter with
your current address and contact information.
Another reason why there are
so many uncashed checks is because sadly claimants have died and their families
do not know about the claim or do not know that they can still pursue a claim.
Benefits
can be paid to a claimant's estate and heirs.
For information about this, contact the Settlement Facility at info@sfdct.com or at 866-874-6099 or the Claimants' Advisory Committee at info@tortcomm.org.
10.
RECENT COURT ORDERS
The Court recently entered
orders on individual claimant appeals on their denied rupture claims.
Consistent with its earlier rulings, the Court stated that:
The
Plan's language is clear and unambiguous that the decision of the Appeals Judge
is final and binding on the claimants and the Reorganized Dow Corning. The
Court has no authority to modify this language.
As a result, the Court stated that it
could not consider claimants' requests to review the Appeals Judge's decisions.
This means that you cannot challenge the Appeals Judge's ruling on your
individual claim by filing a motion to the Court.
If you have a denied rupture claim that
has gone through Error Correction and Re-review but you believe the claim
should have been approved based on the language in the Operative and/or
Pathology Report(s), contact the Claimants' Advisory Committee at info@tortcomm.org. If your rupture claim was based on an expert's review of
your implant, please do not send these claims to us at this time. There is a
separate motion that is pending that pertains to these claims.
The Court has not ruled on
the other pending motions such as tissue expanders and the Disabilty A dispute.
As soon as we receive any ruling, we will notify you via this newsletter and by
posting the order on our website.
11.
UPDATE ON MDL-926 CLAIMS OFFICE MAILINGS
The MDL-926 Claims Office is
continuing to mail letters to claimants in the Revised Settlement Program who
may be affected by the closing of that office in December 2010. Only claims in
the MDL settlement and not claims in the Dow Corning settlement are
affected by the December 2010 deadline. If you have any questions about your
claim in the MDL-926 settlement, contact the Claims Office for the Revised
Settlement Program at: 1-800-600-0311 or at claimsoffice926@aol.com.
12.
SETTLEMENT FACILITY PAYMENTS TO CLAIMANTS
As of October 31, 2008, the Settlement
Facility – Dow Corning Trust reports that it has issued checks to claimants in
the Dow Corning Settlement Fund totalling $1.046 billion
dollars.
Classes 5, 6.1 and 6.2 – Dow Corning Breast Implant
Claimants
Checks totalling over $418.3 million
dollars have been issued to 21,971 approved rupture claimants. In addition,
approximately 22,589 approved disease claimants have been issued checks
totalling approximately $414.8 million. The
approval rate for Proof of Manufacturer (POM) continues to remain at
approximately 82% for Dow Corning breast implant claims. A breakdown of the
payments cashed from June 1, 2004 through October 31, 2008 by class and benefit
type is listed below:
Cumulative
Cashed Checks for Payments to All Classes (including NOI claims)
June
1, 2004 – October 31, 2008
Class
|
Rupture
|
Explant
|
Increased Explant
|
Explant Assistance Program
|
Expedited Release
|
Disease
|
Medical Conditions in Class 9/10
|
Other
Products Premium Payment
|
Total
|
Class 5
|
$405,340,598.66
|
$133,708,642.09
|
n/a
|
$2,776,141.10
|
$29,733,971.89
|
$410,994,616.10
|
n/a
|
n/a
|
$982,553,969.84
|
Class 6.1
|
$ 12,265,350.51
|
$ 3,895,179.80
|
n/a
|
$ 9,000.00
|
$ 2,413,608.51
|
$ 3,589,618.48
|
n/a
|
n/a
|
$ 22,172,757.30
|
Class 6.2
|
$ 595,000.00
|
$ 71,750.00
|
$174,000
|
$ 0.00
|
$ 43,400.00
|
$ 215,250.00
|
n/a
|
n/a
|
$ 1,099,400.00
|
Class 6.2: 2
|
n/a
|
n/a
|
n/a
|
n/a
|
$ 81,600.00
|
n/a
|
n/a
|
n/a
|
$ 81,600.00
|
Class 6.2: 3
|
n/a
|
n/a
|
n/a
|
n/a
|
$ 63,000.00
|
n/a
|
n/a
|
n/a
|
$ 63,000.00
|
Class 7
|
n/a
|
n/a
|
n/a
|
n/a
|
$20,368,033.34
|
n/a
|
n/a
|
n/a
|
$ 20,368,033.34
|
Class 9
|
$ 125,000.00
|
n/a
|
n/a
|
n/a
|
$ 1,732,145.10
|
n/a
|
$2,822,500
|
$13,957,500
|
$ 18,637,145.10
|
Class 10.1/2
|
$ 6,000.00
|
n/a
|
n/a
|
n/a
|
$ 145,650.00
|
n/a
|
$ 210,625
|
$ 976,125
|
$ 1,338,400.00
|
Total
|
$418,331,949.17
|
$137,675,571.89
|
$174,000
|
$2,785,141.10
|
$54,581,408.84
|
$414,799,484.58
|
$3,033,125
|
$14,933,625
|
$1,046,314,305.58
|
Class 7 – Silicone Gel Material Claims
POM Review: The remaining claims to be reviewed are
primarily foreign claims that require translation.
Disease Cash-Out Offers: A total of 7,221 claimants
in Class 7 have been sent the $3,000 Disease Cash-Out offer. Of this number, 71%
have cashed the check and accepted the payment, 14% have returned the check and
asked for a full disease review, and 15% are pending (they have not cashed the
check or returned it to the SF-DCT). Most of the claimants who rejected the
offer have applied for a Disease Option 1 claim (729) and, of this number, 580
reviews have been completed. No claims in Disease Option for Class 7 have
been done. The Settlement Facility has begun issuing Notification of Status
letters; however, no Class 7 disease claims can be paid until all disease
claims have been reviewed and the one-year time deadline to cure deficiencies
has expired. This will take at least another year or more to complete.
The total payout of cashed checks from the capped $57.5
million NPV fund through October 31, 2008 is $20,368,033.34.
Class
7 – Silicone Gel Material Claims
|
#
Class 7 Forms Filed
|
54,753
|
#
of claims that are NOT eligible based on POM review
|
8,400
|
#
of claims that failed marshalling
|
28,976
|
Foreign
Gel Claims Approved & Paid $600
|
620
|
Expedited
Release Claims Approved & Paid $600
|
6,852
|
#
of Disease Cash-Out Offers of $3,000
|
7,221
|
TOTAL
PAYMENTS OR CASH-OUT OFFERS
|
14,693
|
TOTAL
# of Claims Paid (excluding those who rejected the Cash-Out Offer)
|
12,216
|
TOTAL
AMT PAID as of 10-13-08
|
$20,368,033.34
|
13.
OTHER DEADLINE REMINDERS
Please mark your calendar with the following claim
submission deadlines. Note that different deadlines apply to Notice of Intent
(NOI) Claimants and Late Claimants. Please note that most of these deadlines
mean that your claim forms and materials must be received by the SF-DCT
by the posted deadline. Please mail all forms early enough so that they are
received by the deadline listed below. If your claim form is not
received by the deadline listed below, you will not be permitted to file a
claim later.
Deadline Date
|
Type of Deadline
|
January 21, 2009
|
FILING DEADLINE for
LATE CLAIMANTS in CLASS 5 AND 6 to submit all claim forms and supporting
documents. This deadline only applies to LATE CLAIMANTS in Class 5
and 6.
|
March 2, 2009
|
Cure Deadline for certain claimants who
previously filed a claim for Atypical Neurological Disease Syndrome (ANDS) (consult
the SF-DCT about your specific cure deadline)
|
May 4, 2009
|
Cure Deadline for certain claimants who
previously filed a claim for Systemic Lupus Erythematosus (SLE) (consult the
SF-DCT about your specific cure deadline)
|
July 9, 2009
|
Cure Deadline for certain claimants who
previously filed a claim for Atypical Connective Tissue Disease (ACTD) (consult
the SF-DCT about your specific cure deadline)
|
June 2, 2014
|
Explant Claims submission deadline for timely filed
claimants in Classes 5, 6.1 and 6.2 (NOTE: this deadline does NOT
apply to NOI claimants or Late Claimants)
|
June 3, 2019
|
Disease or Expedited Release Claim
submission deadline for all claims in Classes 5, 6.1 and 6.2 (this deadline
does NOT apply to Late Claimants)
|
If you would like to read prior CAC e-newsletters, they are available on the CAC website by clicking on “Electronic Newsletter.” We urge you to visit the CAC website (www.tortcomm.org) on a regular basis to download or view relevant documents and read updates and new information. To contact the CAC, send an email to: info@tortcomm.org or send a letter to the Post Office Box address for the CAC at:
Claimants' Advisory Committee
P.O. Box 665
St. Marys, Ohio 45885
NOTICE: This document is copyrighted. You are not authorized to post it on any website without express, prior written permission of the Claimants’ Advisory Committee.
|